BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis
Open Access
- 25 July 2025
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 32 (8) , 418
Abstract
Light-chain (AL) amyloidosis is a rare clonal plasma cell disorder that, if left untreated, carries a high risk of organ damage and mortality. Due to the rarity of the disease and the vulnerability of affected organ systems, treatment requires significant caution and nuance. As a plasma cell dyscrasia, AL amyloidosis treatment regimens are often adapted from those used for related disorders, particularly multiple myeloma. Despite substantial progress in research and drug development, optimal treatment strategies for relapsed/refractory (RR) AL amyloidosis remain unclear, and no FDA-approved therapies currently exist for this setting. B-cell maturation antigen (BCMA) has emerged as a promising immunotherapy target, with associated drug classes including antibody–drug conjugates, bispecific antibodies, and CAR-T cell therapies. These therapies have been extensively studied in relapsed/refractory multiple myeloma (RRMM) and are now being explored in the context of RR AL amyloidosis. This review summarizes the current literature on the efficacy and tolerability of BCMA-directed therapies in AL amyloidosis, with a particular emphasis on CAR-T cell therapy and offers comparisons to outcomes observed in RRMM.Keywords
This publication has 68 references indexed in Scilit:
- Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trialCancer, 2023
- Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of CalgaryClinical Lymphoma Myeloma and Leukemia, 2023
- Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot studyThe Lancet Oncology, 2023
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studyThe Lancet Oncology, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosisCytotherapy, 2017
- Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center ExperienceClinical Lymphoma Myeloma and Leukemia, 2016
- Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic ReviewTransplantation and Cellular Therapy, 2009
- Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)Transplantation and Cellular Therapy, 2008